Nachrichten zur Kura Oncology Aktie

Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript

…

Kura Oncology to Participate in Jefferies Global Healthcare Conference

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology executive sells over $57k in company stock By Investing.com

Kura Oncology executive sells over $57k in company stock…

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript

…

Kura Oncology to Report First Quarter 2024 Financial Results

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical…

Earnings call: Kura Oncology reports promising trial results, financial outlook By Investing.com

Earnings call: Kura Oncology reports promising trial results, financial outlook…

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical…

Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript

…

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology files to sell 8.7M shares for its holders

…

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical…

The Biotech Stock That Rocketed 39% Before Unveiling Test Results

Kura Oncology is still a week out from unveiling the results for an AML drug. But shares soared Wednesday.…

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology, Inc. (KURA) Q3 2023 Earnings Call Transcript

…

Kura Oncology files for $150M common stock offering, mixed securities shelf

…

Kura Oncology, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12D inhibitors…

Kura Oncology to Participate in Cantor Global Healthcare Conference 2023

SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology to Report Second Quarter 2023 Financial Results

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Form 8-K Kura Oncology, Inc. For: Jun 13

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Kura Oncology slides on pricing of common stock and pre-funded warrants

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Tesla shares rise, as Logitech, Kura and UnitedHealth fall and other stocks on the move

Among Wednesday's moving stocks, shares of Tesla were headed higher again after the EV maker announced another price hike, while…

Kura Oncology stock falls more than 5% after company announces share offering

Shares of Kura Oncology Inc. KURA dropped nearly 6% in the aftermarket Tuesday after the biotech said it plans to…

Kura Oncology plans for $100M stock and warrants offering

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) –...…

Form 8-K Kura Oncology, Inc. For: May 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

– Late-breaking abstracts scheduled for publication on the EHA website at 16:00 CET on Thursday, June 1, 2023 –...…

Kura Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology to Participate in JMP Securities Life Sciences Conference

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology to Report First Quarter 2023 Financial Results

SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology to Participate in Stifel Targeted Oncology Days

SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

– Preclinical data support the potential for FTIs in combination with KRASG12C inhibitors and TKIs to prevent or delay emergence…

Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting

– Presentations to highlight preclinical data supporting combination of FTIs with KRASG12C inhibitors and tyrosine kinase inhibitors –...…

Form 8-K Kura Oncology, Inc. For: Mar 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended…

Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

– Phase 1 trial showed 30% CR rate among 20 NPM1-mutant AML patients treated at recommended Phase 2 dose –...…

dpa-AFX ProFeed